Genetic engineering of insulin expression in nonislet cells: Implications for β-cell replacement therapy for insulin-dependent diabetes mellitus

M. A. Lipes, A. M. Davalli, E. M. Cooper

Research output: Contribution to journalArticle

Abstract

Insulin-dependent diabetes mellitus (IDDM) occurs as a consequence of autoimmune destruction of the insulin-producing pancreatic β-cells. Although progress has been made in the field of islet transplantation, an appealing alternative strategy for β-cell replacement therapy for IDDM is to target insulin expression to non-islet cells. We have recently generated transgenic nonobese diabetic (NOD) mice in which insulin gene expression was targeted to proopiomelanocortin (POMC)-expressing cells of the intermediate lobe (IL) of the pituitary. We have shown that POMC-expressing IL pituitary cells secreted large amounts of mature insulin, similar to islet β-cells. However, in contrast to the insulin-producing islet β-cells, the insulin-producing IL pituitary cells were not attacked by the immune system. Remarkably, transplantation of small amounts of the transgenic IL tissues into diabetic NOD mice resulted in the restoration of near-normogylcemia and the complete reversal of diabetic symptoms. In separate experiments, IL allografts showed enhanced viability and were highly vascularized, compared with similarly transplanted islet allografts. These features are highly advantageous in the transplantation setting and demonstrate the considerable potential of these non-islet cell types for insulin-gene delivery in IDDM.

Original languageEnglish
Pages (from-to)2-5
Number of pages4
JournalActa Diabetologica
Volume34
Issue number1
DOIs
Publication statusPublished - Mar 1997

Fingerprint

Genetic Engineering
Cell- and Tissue-Based Therapy
Type 1 Diabetes Mellitus
Insulin
Intermediate Pituitary Gland
Pro-Opiomelanocortin
Inbred NOD Mouse
Islets of Langerhans
Allografts
Transplantation
Islets of Langerhans Transplantation
Transgenic Mice
Immune System
Gene Expression
Genes

Keywords

  • Diabetes
  • Insulin gene expression
  • Intermediate pituitary
  • Transgenic NOD mice

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Genetic engineering of insulin expression in nonislet cells : Implications for β-cell replacement therapy for insulin-dependent diabetes mellitus. / Lipes, M. A.; Davalli, A. M.; Cooper, E. M.

In: Acta Diabetologica, Vol. 34, No. 1, 03.1997, p. 2-5.

Research output: Contribution to journalArticle

@article{18c71ec8bb0444e592b5fb6fe7d3f424,
title = "Genetic engineering of insulin expression in nonislet cells: Implications for β-cell replacement therapy for insulin-dependent diabetes mellitus",
abstract = "Insulin-dependent diabetes mellitus (IDDM) occurs as a consequence of autoimmune destruction of the insulin-producing pancreatic β-cells. Although progress has been made in the field of islet transplantation, an appealing alternative strategy for β-cell replacement therapy for IDDM is to target insulin expression to non-islet cells. We have recently generated transgenic nonobese diabetic (NOD) mice in which insulin gene expression was targeted to proopiomelanocortin (POMC)-expressing cells of the intermediate lobe (IL) of the pituitary. We have shown that POMC-expressing IL pituitary cells secreted large amounts of mature insulin, similar to islet β-cells. However, in contrast to the insulin-producing islet β-cells, the insulin-producing IL pituitary cells were not attacked by the immune system. Remarkably, transplantation of small amounts of the transgenic IL tissues into diabetic NOD mice resulted in the restoration of near-normogylcemia and the complete reversal of diabetic symptoms. In separate experiments, IL allografts showed enhanced viability and were highly vascularized, compared with similarly transplanted islet allografts. These features are highly advantageous in the transplantation setting and demonstrate the considerable potential of these non-islet cell types for insulin-gene delivery in IDDM.",
keywords = "Diabetes, Insulin gene expression, Intermediate pituitary, Transgenic NOD mice",
author = "Lipes, {M. A.} and Davalli, {A. M.} and Cooper, {E. M.}",
year = "1997",
month = "3",
doi = "10.1007/s005920050056",
language = "English",
volume = "34",
pages = "2--5",
journal = "Acta Diabetologica",
issn = "0940-5429",
publisher = "Springer-Verlag Italia s.r.l.",
number = "1",

}

TY - JOUR

T1 - Genetic engineering of insulin expression in nonislet cells

T2 - Implications for β-cell replacement therapy for insulin-dependent diabetes mellitus

AU - Lipes, M. A.

AU - Davalli, A. M.

AU - Cooper, E. M.

PY - 1997/3

Y1 - 1997/3

N2 - Insulin-dependent diabetes mellitus (IDDM) occurs as a consequence of autoimmune destruction of the insulin-producing pancreatic β-cells. Although progress has been made in the field of islet transplantation, an appealing alternative strategy for β-cell replacement therapy for IDDM is to target insulin expression to non-islet cells. We have recently generated transgenic nonobese diabetic (NOD) mice in which insulin gene expression was targeted to proopiomelanocortin (POMC)-expressing cells of the intermediate lobe (IL) of the pituitary. We have shown that POMC-expressing IL pituitary cells secreted large amounts of mature insulin, similar to islet β-cells. However, in contrast to the insulin-producing islet β-cells, the insulin-producing IL pituitary cells were not attacked by the immune system. Remarkably, transplantation of small amounts of the transgenic IL tissues into diabetic NOD mice resulted in the restoration of near-normogylcemia and the complete reversal of diabetic symptoms. In separate experiments, IL allografts showed enhanced viability and were highly vascularized, compared with similarly transplanted islet allografts. These features are highly advantageous in the transplantation setting and demonstrate the considerable potential of these non-islet cell types for insulin-gene delivery in IDDM.

AB - Insulin-dependent diabetes mellitus (IDDM) occurs as a consequence of autoimmune destruction of the insulin-producing pancreatic β-cells. Although progress has been made in the field of islet transplantation, an appealing alternative strategy for β-cell replacement therapy for IDDM is to target insulin expression to non-islet cells. We have recently generated transgenic nonobese diabetic (NOD) mice in which insulin gene expression was targeted to proopiomelanocortin (POMC)-expressing cells of the intermediate lobe (IL) of the pituitary. We have shown that POMC-expressing IL pituitary cells secreted large amounts of mature insulin, similar to islet β-cells. However, in contrast to the insulin-producing islet β-cells, the insulin-producing IL pituitary cells were not attacked by the immune system. Remarkably, transplantation of small amounts of the transgenic IL tissues into diabetic NOD mice resulted in the restoration of near-normogylcemia and the complete reversal of diabetic symptoms. In separate experiments, IL allografts showed enhanced viability and were highly vascularized, compared with similarly transplanted islet allografts. These features are highly advantageous in the transplantation setting and demonstrate the considerable potential of these non-islet cell types for insulin-gene delivery in IDDM.

KW - Diabetes

KW - Insulin gene expression

KW - Intermediate pituitary

KW - Transgenic NOD mice

UR - http://www.scopus.com/inward/record.url?scp=0030959913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030959913&partnerID=8YFLogxK

U2 - 10.1007/s005920050056

DO - 10.1007/s005920050056

M3 - Article

C2 - 9134049

AN - SCOPUS:0030959913

VL - 34

SP - 2

EP - 5

JO - Acta Diabetologica

JF - Acta Diabetologica

SN - 0940-5429

IS - 1

ER -